Evidence map›Paper›PMID 41212257›Full record

SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025

Otoprotective measures for cisplatin-based chemoradiotherapy-induced toxicity in patients with head and neck cancer: a systematic review and meta-analysis.

Katia Regina Marchetti, Leonardo Duarte Guerra, Pedro Angelo Luzini Gondim, Gilberto de Castro Junior

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Journal of clinical medicine · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Katia Regina MarchettiDepartment of Clinical Oncology, Cancer Institute of the State of São Paulo, University of São Paulo, São Paulo, São Paulo, Brazil. drakatia.marchetti@gmail.com.ORCID http://orcid.org/0000-0003-3652-9486
Leonardo Duarte GuerraDepartment of Clinical Oncology, Base Hospital, Federal District, Brasília, Federal District, Brazil.ORCID http://orcid.org/0000-0002-1032-6405
Pedro Angelo Luzini GondimDepartment of Clinical Oncology, Base Hospital, Federal District, Brasília, Federal District, Brazil.ORCID http://orcid.org/0009-0005-2752-9718
Gilberto de Castro JuniorDepartment of Clinical Oncology, Cancer Institute of the State of São Paulo, University of São Paulo, São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0000-0001-8765-3044

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo systematically review and meta-analyze the available literature on otoprotective measures for cisplatin-induced ototoxicity in head and neck squamous cell cancer (SCC), with a focus on interventions capable of reducing toxicity while preserving oncologic outcomes.

methodsThe PubMed Central, MEDLINE, and SciELO databases were searched in March 2024. The inclusion criteria were prospective or retrospective cohort studies, case‒control studies, and phase II or III trials in which otoprotective measures for ototoxicity induced by high-dose cisplatin-based concomitant chemoradiotherapy (CRT), 100 mg/m

resultsOf the 216 identified articles, 13 were assessed in the final analysis. All studies (n = 13) used high-dose cisplatin-based CRT as the standard regimen. The intervention regimens were: six studies used low-dose cisplatin-based CRT (≤ 40 mg/m

conclusionThrough our systematic review, we identified a limited number of studies of measures to prevent the ototoxic effects of high-dose cisplatin-based CRT. Most studies had negative results, small patient populations, and were of low quality. Only low-dose cisplatin-based CRT tended to reduce the incidence of ototoxicity while maintaining survival data similar to those of high-dose cisplatin-based CRT.

trial registrationNot applicable.

Indexed as

Antineoplastic AgentsChemoradiotherapyCisplatinHead and Neck NeoplasmsOtotoxicityProtective AgentsSquamous Cell Carcinoma of Head and NeckHumansThiosulfatesAntineoplastic AgentsCisplatinProtective Agentssodium thiosulfateThiosulfatesChemoradiotherapyCisplatinHead and neck squamous cell carcinomaOtotoxicity

Identifiers

PMID41212257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.